Immunogen Inc (IMGN)

5.66
NASDAQ : Health Care
Prev Close 5.90
Day Low/High 5.46 / 6.00
52 Wk Low/High 1.51 / 8.04
Avg Volume 2.72M
Exchange NASDAQ
Shares Outstanding 89.35M
Market Cap 527.16M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Short Interest In ImmunoGen Makes 10.6% Move

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 1,348,572 share increase in total short interest for ImmunoGen, Inc. , to 14,103,629, an increase of 10.57% since 05/31/2017.

ImmunoGen Presents Data From Phase I Study Of IMGN779 In Acute Myeloid Leukemia

ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, presented data from the ongoing Phase 1 study evaluating single agent IMGN779 in patients with...

IMGN Crosses Above Average Analyst Target

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $5.10, changing hands for $5.42/share.

First Week Of IMGN August 18th Options Trading

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the August 18th expiration.

ImmunoGen And Sanofi Amend License Agreements

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company and an affiliate of Sanofi have amended their license...

ImmunoGen Announces Webcast Of Presentation At The Jefferies Global Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, president and chief executive officer, will present at...

IMGN Crosses Above Average Analyst Target

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $5.10, changing hands for $5.40/share.

ImmunoGen Announces New Clinical Data With Mirvetuximab Soravtansine In Ovarian Cancer To Be Presented At 2017 ASCO Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced promising safety and efficacy data from monotherapy and combination...

ImmunoGen Reports Recent Progress And First Quarter 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and reported financial results for the quarter ended...

ImmunoGen Announces Results From Mirvetuximab Soravtansine Phase 1 First-in-Human Dose-Escalation Trial Published In Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the results from a Phase 1 dose-escalation study evaluating...

ImmunoGen Announces Conference Call To Discuss Its First Quarter 2017 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

Commit To Buy ImmunoGen At $2, Earn 9.6% Annualized Using Options

Investors eyeing a purchase of ImmunoGen, Inc. shares, but cautious about paying the going market price of $2.95/share, might benefit from considering selling puts among the alternative strategies at their disposal.

ImmunoGen Presents Phase 1 Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that data from a mirvetuximab soravtansine (IMGN853) Phase 1 biopsy...

ImmunoGen Announces Presentations At AACR Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that nine abstracts highlighting the breath of the Company's expertise...

ImmunoGen Reports Recent Progress And Operating Results For Six-Month Period And Quarter Ended December 31, 2016

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and reported financial results for the six-month period...

Short Interest Jumps 11.2% For IMGN

The most recent short interest data has been released for the 01/31/2017 settlement date, which shows a 1,370,280 share increase in total short interest for ImmunoGen, Inc. , to 13,619,943, an increase of 11.19% since 01/13/2017.

ImmunoGen Announces Webcasts Of Presentations At Upcoming Investor Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming...

ImmunoGen Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer

ImmunoGen Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been dosed in FORWARD I, the Company's Phase...

ImmunoGen Announces Conference Call To Discuss Its Results For Six-Month Period And Quarter Ended December 31

ImmunoGen Announces Conference Call To Discuss Its Results For Six-Month Period And Quarter Ended December 31

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

ImmunoGen Announces Departure Of Sandra Poole

ImmunoGen Announces Departure Of Sandra Poole

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Sandra Poole, Executive Vice President, Technical Operations...

Short Interest Declines 10.4% For IMGN

Short Interest Declines 10.4% For IMGN

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 1,295,231 share decrease in total short interest for ImmunoGen, Inc. , to 11,157,217, a decrease of 10.40% since 12/15/2016.

ImmunoGen Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology

ImmunoGen Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology

ImmunoGen, Inc. (Nasdaq:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that results from the Phase 1 expansion cohort evaluating mirvetuximab...

ImmunoGen Announces Webcast Of Presentation And Q&A At The 35th Annual J. P. Morgan Healthcare Conference

ImmunoGen Announces Webcast Of Presentation And Q&A At The 35th Annual J. P. Morgan Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Mark Enyedy, President and CEO, will present at the upcoming 35 th Annual...

Preclinical Data On IMGN632, A Novel CD123-Targeting ADC, Presented At ASH Annual Meeting

Preclinical Data On IMGN632, A Novel CD123-Targeting ADC, Presented At ASH Annual Meeting

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that preclinical data on IMGN632, a novel CD123-targeting ADC, were...

ImmunoGen To Present Preclinical Data Highlighting Potential Of Combining Mirvetuximab Soravtansine With An Immune Checkpoint Inhibitor At SITC 2016 Annual Meeting

ImmunoGen To Present Preclinical Data Highlighting Potential Of Combining Mirvetuximab Soravtansine With An Immune Checkpoint Inhibitor At SITC 2016 Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced new preclinical data that demonstrate the potential for enhanced...

ImmunoGen Announces Preclinical Data Presentations For Two ADCs With Novel IGN Payloads At Upcoming 58th ASH Annual Meeting

ImmunoGen Announces Preclinical Data Presentations For Two ADCs With Novel IGN Payloads At Upcoming 58th ASH Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new preclinical data on the Company's novel IGN ADCs, IMGN632 and...

ImmunoGen Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights

ImmunoGen Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reported financial results and reviewed business highlights for the three-month...